Findings
- SGLT-2 inhibitors were associated with a significantly reduced risk of ASCVD, hospitalization due to heart failure (HHI), and renal events in patients with type 2 diabetes without atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease.
- No significant differences were found between dapagliflozin and empagliflozin.
Why this matters
- Conflicting data regarding the differences between individual SGLT2is; moreover, no previous study has directly compared them in terms of clinical outcomes.
Study design
- Retrospective analysis of propensity-score matching users of dapagliflozin (921), empagliflozin (921) and DPP4is (1,842)
- Median follow-up was 37.3, 37.1, and 55.1 months for dapagliflozin, empagliflozin and DPP4is.
- Funding: None
Key results
- Significantly lower incidence of composite coronary events with SGLT2is vs.DPP4is (dapagliflozin: aHR: 0.267; p = 0.002 and empagliflozin: aHR: 0.467; p = 0.030)
- No significant difference between dapagliflozin and empagliflozin (aHR: 2.196; p = 0.156)
- Compared to DPP4is, both SGLT2is significantly improved composite HHI and renal events (dapagliflozin: aHR:& 0.186; p = 0.001 and empagliflozin: aHR: 0.358; p = 0.007).
- After 24 and 36 For months, low-density lipoprotein cholesterol levels were significantly higher and HbA1c levels were significantly lower with empagliflozin than with DPP4is and dapagliflozin.
Limitations
- Small number of cases
- Short follow-up
- Exclusion of patients with previous events
- Retrospective study
- Potential unconsidered confounding factors
This full text is unfortunately reserved for relatives medical professionals
You have reached the maximum number of articles for unregistered visitors
Source — https://www.univadis.de/viewarticle/typ-2-diabetes-kardiovaskularer-und-renaler-nutzen-moderner-antidiabetika
Comments are closed.